Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.

A number of other analysts also recently weighed in on AGIO. Oppenheimer Holdings, Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 18th. ValuEngine raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Cann reaffirmed a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, April 19th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $61.00 price target on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $62.88.

Shares of Agios Pharmaceuticals (AGIO) traded up 0.75% on Thursday, reaching $57.81. 310,024 shares of the company’s stock were exchanged. The company’s market cap is $2.79 billion. The firm’s 50-day moving average price is $51.10 and its 200 day moving average price is $49.19. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The company had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.65 million. During the same quarter in the prior year, the firm posted ($0.64) EPS. The firm’s quarterly revenue was down 66.4% on a year-over-year basis. Equities research analysts predict that Agios Pharmaceuticals will post ($6.44) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/16/agios-pharmaceuticals-inc-nasdaqagio-upgraded-to-buy-by-bidaskclub.html.

In related news, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $50.06, for a total value of $150,180.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares of the company’s stock, valued at approximately $150,180. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total transaction of $95,895.60. Following the completion of the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. In the last three months, insiders sold 26,600 shares of company stock valued at $1,394,718. 10.55% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the stock. FMR LLC increased its position in shares of Agios Pharmaceuticals by 0.5% in the first quarter. FMR LLC now owns 6,331,747 shares of the biopharmaceutical company’s stock valued at $369,774,000 after buying an additional 32,931 shares during the last quarter. BB Biotech AG increased its position in shares of Agios Pharmaceuticals by 1.1% in the first quarter. BB Biotech AG now owns 2,839,528 shares of the biopharmaceutical company’s stock valued at $165,828,000 after buying an additional 30,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,597,391 shares of the biopharmaceutical company’s stock valued at $151,688,000 after buying an additional 129,159 shares during the last quarter. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock valued at $126,556,000 after buying an additional 2,141,768 shares during the last quarter. Finally, State Street Corp increased its position in shares of Agios Pharmaceuticals by 13.8% in the fourth quarter. State Street Corp now owns 1,240,585 shares of the biopharmaceutical company’s stock valued at $51,772,000 after buying an additional 150,244 shares during the last quarter. 83.66% of the stock is owned by institutional investors and hedge funds.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.